Regenerative Medicine Leader Nuoyi Mayer Completes Nearly RMB 300 Million Series C Financing Led by National New Materials Fund

The successful completion of this round of financing further highlights Neo Modulus's comprehensive strength and development potential in the high-end biomedical materials field. The funds will mainly be used for the commercial promotion, clinical trials, and implementation of the internationalization strategy of the company’s multiple innovative medical device products.

Neo Modulus was founded in March 2017 by a team of Chinese and German scientists led by a member selected for China's National Key Talent Project. It is an innovative enterprise focused on the research, development, production, and commercialization of regenerative implantable medical devices. The company adheres to the goal of independent innovation with first-of-its-kind products in China and global leadership, mastering core technologies from advanced raw material design, proprietary equipment development, key process preparation, to clinical application of its products. It has achieved industrialized applications for key technology routes in the field of tissue engineering materials, including electrospinning, 3D printing, and chemical synthesis. Its rich product portfolio covers various forms such as membranes, bone materials, gels, agents, and microspheres, extending across multiple clinical departments including dentistry, ophthalmology, reproductive medicine, sports medicine, otolaryngology, and surgery. Neo Modulus has become one of the most comprehensive solution providers in China’s regenerative medicine materials sector, boasting the widest product coverage and the most advanced technology.

Since its establishment, Neo Modulus has successively completed clinical trials and launched several products that are "firsts in China" or "internationally leading." In the field of dentistry, the company has obtained three Class III medical device registration certificates in China, providing comprehensive solutions for soft and hard tissue repair for patients. Among them, "WenNuo^®"Gingival Repair Membrane" is China's first Class III passive implant national innovative dental instrument, and has been used in benchmark hospitals such as West China Hospital of Stomatology, Sichuan University; in the field of otorhinolaryngology, the innovative medical device "Oleyu.^®The "Expansive Hemostatic Sponge" has been adopted for use in multiple Class III hospitals. Additionally, a range of innovative products that the company has developed in ophthalmology, reproductive medicine, sports medicine, and surgery are currently undergoing clinical trials. Some projects have received approval under the National Key Research and Development Program, with expectations that several innovative Class III medical devices will be approved for market release within the next five years. In the future, the company will accelerate the commercialization and market promotion of its products, allowing more clinicians and patients to benefit from domestically produced innovative medical device products.

The company is simultaneously advancing its international layout, striving to become a leading enterprise in the global regenerative medicine field. In 2024, the company's innovative medical device, the Neosprout Nasal Hemostatic Sponge, successively received CE MDR and FDA approval for market release, demonstrating that this innovative product has achieved internationally high standards in both efficacy and safety. Multiple innovative medical devices from the company are currently undergoing overseas registration and market promotion simultaneously, realizing the globalization of "Made in China" regenerative medicine materials.

Neo Modulus has established four R&D and production bases in Suzhou, Weifang, Taicang, and Shanghai, along with the Beijing Medical Center and an overseas laboratory in Freiburg, Germany, forming a "4+1+1" R&D innovation structure. The company has built cleanroom facilities with a total area exceeding 30,000 square meters, enabling rapid response to downstream demands. It provides reliable solutions and products for clinicians and patients while continuously contributing to local economic development and job creation.

Neo ModulusExpressed: Great thanks to the New Materials Fund for its support to Neo Modulus, and also gratitude to all the existing shareholders for their trust in the company. Neo Modulus has entered a critical stage of accelerating commercialization. The company will continue to adhere to the "innovation + internationalization" development strategy, providing a broader product portfolio to benefit patients worldwide.

Shenzhen Capital Group Co., Ltd. was established in 1999 by the Shenzhen Municipal Government with guidance and social capital investment. With the mission of "discovering and achieving great enterprises," the company is committed to being an explorer and nurturer of innovative value. It has now developed into a comprehensive investment group centered on venture capital, managing a total fund size exceeding 480 billion yuan. The Shenzhen Capital Group's New Materials Fund for Manufacturing Transformation and Upgrading is a specific investment vehicle of the National Manufacturing Transformation and Upgrading Fund, primarily focusing on investments in the new materials sector.